









Markets
/
Stocks
/
nasdaq-cytk
/

Cytokinetics Inc

CYTK

62.340USD

+2.100+3.49%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

7.61BMarket Cap

LossP/E TTM



Cytokinetics Inc

62.340

+2.100+3.49%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Cytokinetics Inc

Currency: USD Updated: 2026-02-06

Key Insights

Cytokinetics Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 53 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 89.82.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Cytokinetics Inc's Score

Industry at a Glance

Industry Ranking

53 / 392

Overall Ranking

163 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Cytokinetics Inc Highlights

StrengthsRisks

Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The Company is engaged in the commercialization of aficamten, a cardiac myosin inhibitor, and is being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive hypertrophic cardiomyopathy. The Company is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF); CK-586, a cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.

Growing

The company is in a growing phase, with the latest annual income totaling USD 18.47M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 18.47M.

Fairly Valued

The company’s latest PE is -9.88, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 145.87M shares, increasing 0.10% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 627.00 shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.04.

Analyst Rating

Based on 20 analysts

Buy

Current Rating

89.824

Target Price

+49.11%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Cytokinetics Inc is 6.45, ranking 252 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 1.94M, representing a year-over-year increase of 318.14%, while its net profit experienced a year-over-year increase of 90.71%.

Score

Industry at a Glance

Previous score

6.45

Change



Financials

4.47

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.23

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

3.09

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.48

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Cytokinetics Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Cytokinetics Inc is 6.60, ranking 250 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -9.88, which is -50.94% below the recent high of -4.85 and -100.66% above the recent low of -19.82.

Score

Industry at a Glance

Previous score

6.60

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 53/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Cytokinetics Inc is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 79.00, with a high of 120.00 and a low of 55.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 20 analysts

Buy

Current Rating

89.824

Target Price

+49.11%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Cytokinetics Inc

CYTK

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Cytokinetics Inc is 6.98, ranking 125 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 66.27 and the support level at 59.23, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.44

Change

0.54

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.554

Neutral

RSI(14)

47.041

Neutral

STOCH(KDJ)(9,3,3)

28.304

Sell

ATR(14)

2.706

Low Volatility

CCI(14)

-144.061

Sell

Williams %R

67.495

Sell

TRIX(12,20)

0.030

Sell

StochRSI(14)

46.480

Buy

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

63.198

Sell

MA10

63.712

Sell

MA20

63.669

Sell

MA50

63.638

Sell

MA100

61.184

Buy

MA200

48.957

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Cytokinetics Inc is 10.00, ranking 1 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 132.55%, representing a quarter-over-quarter decrease of 2.37%. The largest institutional shareholder is The Vanguard, holding a total of 12.02M shares, representing 9.83% of shares outstanding, with 0.69% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

T. Rowe Price Investment Management, Inc.

19.08M

+8.40%

BlackRock Institutional Trust Company, N.A.

13.61M

-1.49%

The Vanguard Group, Inc.

Star Investors

11.83M

-1.06%

Fidelity Management & Research Company LLC

9.43M

+13.08%

Wellington Management Company, LLP

7.41M

-5.35%

State Street Investment Management (US)

5.62M

-11.85%

Deep Track Capital LP

4.30M

+17.81%

Geode Capital Management, L.L.C.

3.04M

+1.53%

BofA Global Research (US)

3.01M

+15.86%

Fidelity Institutional Asset Management

3.66M

+25.03%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Cytokinetics Inc is 6.92, ranking 20 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.57. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.